Spotlight
Clinical Role
Clinical
Supplement Spotlight
CE
Subscribe
Press Release
Article
Camber Pharmaceuticals Announces Addition of Bortezomib for Injection
Key Takeaways
- Bortezomib for Injection is a proteasome inhibitor for treating multiple myeloma and mantle cell lymphoma in adults.
- The medication is available in a 3.5 mg strength, packaged in a single-dose vial.
Bortezomib for Injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and treatment of adult patients with mantle cell lymphoma.
Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection.
Bortezomib for Injection is a proteasome inhibitor indicated for:
- treatment of adult patients with multiple myeloma
- treatment of adult patients with mantle cell lymphoma
Bortezomib for Injection is available in 3.5 mg strength, packaged in a single-dose vial.
To find out more information on Bortezomib for Injection please visit: www.camberpharma.com/bortezomib
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Videos
Related Content
